SCHEMBL21565713

SCHEMBL21565713

Cc1cc(B2OC(C)(C)C(C)(C)O2)ccc1CN1CCN(C)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
POLB P06746 3/20 0.42
TDP1 Q9NUW8 3/20 0.42
KDM4E B2RXH2 2/20 0.42
ROCK1 Q13464 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
CHKA P35790 1/20 0.39
NR1H2 P55055 1/20 0.39
MTNR1A P48039 1/20 0.38
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
LPL P06858 1/20 0.36
LIPG Q9Y5X9 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
MC4R P32245 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29725194 1.00 ALDH1A1 (0.42) ALDH1A1POLBTDP1KDM4EROCK1
SCHEMBL2799913 0.90 KMT2A (0.49) ALDH1A1KDM4EROCK1KMT2ALPL
SCHEMBL2801616 0.87 CYP2A13 (0.51) POLBTDP1KDM4EROCK1KMT2A
SCHEMBL2800281 0.86 NPC1 (0.42) ALDH1A1ROCK1KMT2AMEN1LPL
SCHEMBL18579955 0.86 ROCK1 (0.53) ALDH1A1POLBTDP1KDM4EROCK1
SCHEMBL16795211 0.82 POLB (0.46) ALDH1A1POLBTDP1KDM4EROCK1
SCHEMBL22532810 0.81 KDM4E (0.49) ALDH1A1POLBTDP1KDM4EROCK1
SCHEMBL16795319 0.80 POLB (0.44) ALDH1A1POLBTDP1KDM4EROCK1
SCHEMBL16795392 0.79 KDM4E (0.43) ALDH1A1POLBTDP1KDM4ECHKA
SCHEMBL429722 0.79 LMNA (0.53) ALDH1A1KDM4ECHKALPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503473-B2 Triazolopyrimidine compounds and their use in treating cancer DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-12-23 US disclosed
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
US-11851432-B2 Triazolopyrimidine compounds and their use in treating cancer DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-12-26 US disclosed
EP-4134368-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-02-15 EP disclosed
EP-4134368-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-02-15 EP disclosed
CN-115028637-A Triazolopyrimidine compounds and their use for the treatment of cancer 迪哲(江苏)医药股份有限公司 2022-09-09 CN disclosed
CN-115028636-A Triazolopyrimidine compounds and their use for the treatment of cancer 迪哲(江苏)医药股份有限公司 2022-09-09 CN disclosed
EP-3790879-B1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2022-06-29 EP disclosed
EP-3790879-B1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2022-06-29 EP disclosed
CN-112469721-B Triazolopyrimidine compounds and their use for the treatment of cancer 迪哲(江苏)医药股份有限公司 2022-06-07 CN disclosed
US-20210340150-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2021-11-04 US disclosed
US-20210340150-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2021-11-04 US disclosed
US-11084827-B2 Triazolopyrimidine compounds and their use in treating cancer DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2021-08-10 US disclosed
US-11084827-B2 Triazolopyrimidine compounds and their use in treating cancer DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2021-08-10 US disclosed
US-20210087196-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2021-03-25 US disclosed
US-20210087196-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2021-03-25 US disclosed
CN-112469721-A Triazolopyrimidine compounds and their use for the treatment of cancer 迪哲(江苏)医药股份有限公司 2021-03-09 CN disclosed
WO-2019215316-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503473-B2 Triazolopyrimidine compounds and their use in treating cancer ABCC4, ABCB1, SLC16A3 ALDH1A1 205/4885POLB 1719/4885TDP1 818/4885
US-11084827-B2 Triazolopyrimidine compounds and their use in treating cancer ABCC4, ABCB1, SLC16A3 ALDH1A1 205/4885POLB 1719/4885TDP1 818/4885
US-20210087196-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER ABCC4, ABCB1, SLC16A3 ALDH1A1 205/4885POLB 1719/4885TDP1 818/4885
US-20210340150-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER ABCC4, ABCB1, SLC16A3 ALDH1A1 205/4885POLB 1719/4885TDP1 818/4885
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER ABCC4, ABCB1, SLC16A3 ALDH1A1 205/4885POLB 1719/4885TDP1 818/4885
US-11851432-B2 Triazolopyrimidine compounds and their use in treating cancer ABCC4, ABCB1, SLC16A3 ALDH1A1 205/4885POLB 1719/4885TDP1 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.